Multi-Omics Driven Development of Effective Cell Therapies
ImmunoMind has raised $150K in total funding. The most recent round was Pre-Seed. The last funding was announced in January 2022.
ImmunoMind's investors include SkyDeck Berkeley.
ImmunoMind is headquartered in Berkeley, United States.
Multi-Omics Driven Development of Effective Cell Therapies
ImmunoMind is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmunoMind — Funding & Investors." VCBacked, January 1, 2022, https://www.vcbacked.co/company/immunomind. Accessed August 14, 2026.
VCBacked. (2022). ImmunoMind — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/immunomind
{{cite web |title=ImmunoMind — Funding & Investors |url=https://www.vcbacked.co/company/immunomind |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated